This approach doesn't eliminate clinical trials but it augments the discovery process by highlighting productive areas of research. Perhaps the most difficut hurdle to overcome for Insitro is cultural: the huge pharmaceutical industry is used to relying on manual research and may have difficulty trusting machine learning guidance. However, this hasn't prevented their solution from being adopted by Gilead in their search for treatements for liver disease. It is also collaborating with Bristol Myers Squibb in ALS and dementia research. Should these partnerships prove successful Insitro stands to really shake up the pharmaceutical industry.